title: Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.
abstract: BACKGROUND
  Hepatic steatosis is common in patients with chronic hepatitis C virus (HCV) infection, and its occurrence may be related to both host and viral factors. Relationship between improvement in steatosis and response to anti-viral treatment remains unclear. This study assessed the factors associated with steatosis in patients infected with genotype 4 HCV, and to correlate degree of changes in steatosis with host factors and response to treatment.
  
  
  METHODS
  Records of 175 patients with chronic genotype 4 HCV infection, who had received interferon and ribavirin combination therapy, were reviewed retrospectively to extract data on body mass index (BMI), presence of diabetes mellitus, and liver histology findings. Paired BMI data and liver biopsies (pre- and 24-weeks post-treatment) were available in 86 patients. Baseline steatosis and its changes (before and after treatment) were the dependent variables in a univariate and multivariate analyses.
  
  
  RESULTS
  Steatosis was found in 88/175 (50.3%) of baseline biopsies. Its presence was related to baseline BMI (r=0.33, P<0.01), but not with viral load, or grade of liver inflammation or fibrosis. On follow up, improvement in steatosis was significantly associated with degree of weight loss but not with response to anti-viral treatment.
  
  
  CONCLUSIONS
  Steatosis is common in genotype 4 HCV infection, and its presence appears to be related to high BMI, but not to viral load or degree of liver injury.
authors.affiliation: Hepatology and Tropical Medicine Department, Cairo University, Cairo, Egypt.
authors.forename: G
authors.initials: G
authors.lastname: Esmat
authors.forename: Wafaa
authors.initials: W
authors.lastname: El Akel
authors.forename: M
authors.initials: M
authors.lastname: Metwally
authors.forename: A
authors.initials: A
authors.lastname: Soliman
authors.forename: W
authors.initials: W
authors.lastname: Doss
authors.forename: M Abdel
authors.initials: MA
authors.lastname: Hamid
authors.forename: M
authors.initials: M
authors.lastname: Kamal
authors.forename: K
authors.initials: K
authors.lastname: Zalata
authors.forename: H
authors.initials: H
authors.lastname: Khattab
authors.forename: M
authors.initials: M
authors.lastname: El-Kassas
authors.forename: M
authors.initials: M
authors.lastname: Esmat
authors.forename: A
authors.initials: A
authors.lastname: Hasan
authors.forename: M
authors.initials: M
authors.lastname: El-Raziky
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D015992:Body Mass Index; D004279:DNA, Viral / Q000032:analysis*; D004359:Drug Therapy, Combination; D005234:Fatty Liver / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D015431:Weight Loss; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D012254:Ribavirin; D007372:Interferons
references.citation: Clin Gastroenterol Hepatol. 2005 Jun;3(6):604-9
references.pmid: 15952103
references.citation: J Interferon Cytokine Res. 2001 Jul;21(7):453-61
references.pmid: 11506737
references.citation: J Hepatol. 1999;31 Suppl 1:160-7
references.pmid: 10622580
references.citation: Hepatology. 1999 Apr;29(4):1215-9
references.pmid: 10094967
references.citation: Antiviral Res. 2003 Oct;60(2):125-7
references.pmid: 14638408
references.citation: J Hepatol. 2001 Sep;35(3):432-3
references.pmid: 11592609
references.citation: J Viral Hepat. 1998 Jul;5(4):249-53
references.pmid: 9751011
references.citation: J Hepatol. 1995 Jun;22(6):696-9
references.pmid: 7560864
references.citation: J Med Virol. 2005 Apr;75(4):550-8
references.pmid: 15714492
references.citation: Scand J Gastroenterol. 2002 Feb;37(2):226-32
references.pmid: 11843062
references.citation: Am J Gastroenterol. 2000 Nov;95(11):3211-7
references.pmid: 11095344
references.citation: J Viral Hepat. 2005 Sep;12(5):531-5
references.pmid: 16108770
references.citation: Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:52-5
references.pmid: 16225474
references.citation: N Engl J Med. 1997 Jan 30;336(5):347-56
references.pmid: 9011789
references.citation: Am J Gastroenterol. 1999 Sep;94(9):2467-74
references.pmid: 10484010
references.citation: Hepatology. 2003 Sep;38(3):639-44
references.pmid: 12939590
references.citation: Liver. 1999 Oct;19(5):432-7
references.pmid: 10533803
references.citation: Gut. 2004 Mar;53(3):420-4
references.pmid: 14960527